We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SGEN Seagen Inc

-0.49 (-0.23%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 1,304,128
Bid Price 206.50
Ask Price 216.54
News -
Day High 213.97


52 Week Range


Day Low 212.44
Share Name Share Symbol Market Stock Type
Seagen Inc SGEN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.49 -0.23% 212.72 23:00:10
Open Price Low Price High Price Close Price Previous Close
213.60 212.44 213.97 212.72 213.21
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
18,486 1,304,128 US$ 213.20 US$ 278,045,906 - 116.08 - 217.55
Last Trade Type Quantity Price Currency
16:07:56 average 6,027 US$ 212.72 USD

Seagen (SGEN) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Seagen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
40.13B 188.66M - 1.96B -610.31M -3.23 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Seagen News

Date Time Source News Article
11/30/202317:04Dow Jones NewsAstellas, Seagen: Cancer Treatment Padcev Supplemental..
11/30/202316:00Business WireFDA Grants Priority Review for Supplemental Biologics..
11/13/202320:37Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]
11/13/202319:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
11/13/202318:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
11/13/202317:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
11/09/202315:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securities
11/03/202311:00Business WireSeagen Highlights First Solid Tumor Data for an ADCETRIS®..
11/02/202312:00Business WireNew Data for ADCETRIS® (brentuximab vedotin) with..
11/01/202307:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/01/202307:09Edgar (US Regulatory)Form 8-K - Current report
11/01/202307:00Business WireSeagen Third Quarter 2023 Financial Results Reflect Strong..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No SGEN Message Board. Create One! See More Posts on SGEN Message Board See More Message Board Posts

Historical SGEN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week213.27215.00212.44213.81845,931-0.55-0.26%
1 Month214.74215.7995211.77213.441,037,949-2.02-0.94%
3 Months205.33217.55203.605212.971,391,8907.393.6%
6 Months195.47217.55190.67205.331,260,49817.258.82%
1 Year121.47217.55116.08190.041,317,48991.2575.12%
3 Years171.87217.55105.43167.351,111,91740.8523.77%
5 Years63.24217.5551.50147.511,070,934149.48236.37%

Seagen Description

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |